Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Smart for Life (SMFL) Competitors

Smart for Life logo
$0.0010 +0.00 (+11.11%)
As of 05/20/2026 02:49 PM Eastern
Compare

SMFL vs. VAXX, ELOX, ORGS, TRVN, and NAVB

Should you buy Smart for Life stock or one of its competitors? MarketBeat compares Smart for Life with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Smart for Life include Vaxxinity (VAXX), Eloxx Pharmaceuticals (ELOX), Orgenesis (ORGS), Trevena (TRVN), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry.

How does Smart for Life compare to Vaxxinity?

Smart for Life (NASDAQ:SMFL) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Vaxxinity N/A N/A N/A

In the previous week, Smart for Life had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Vaxxinity. Smart for Life's average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Vaxxinity Neutral

Smart for Life has higher revenue and earnings than Vaxxinity. Vaxxinity is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

Smart for Life has a beta of 13.95, suggesting that its stock price is 1,295% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -74.37, suggesting that its stock price is 7,537% less volatile than the broader market.

Summary

Smart for Life beats Vaxxinity on 5 of the 8 factors compared between the two stocks.

How does Smart for Life compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Company Net Margins Return on Equity Return on Assets
Eloxx PharmaceuticalsN/A N/A N/A
Smart for Life N/A N/A N/A

Eloxx Pharmaceuticals has a beta of -1907.33, suggesting that its stock price is 190,833% less volatile than the broader market. Comparatively, Smart for Life has a beta of 13.95, suggesting that its stock price is 1,295% more volatile than the broader market.

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 31.7% of Smart for Life shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Smart for Life has higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eloxx PharmaceuticalsN/AN/A-$36.06M-$1.39N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

In the previous week, Smart for Life had 1 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Eloxx Pharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Eloxx Pharmaceuticals Neutral
Smart for Life Neutral

Summary

Smart for Life beats Eloxx Pharmaceuticals on 7 of the 8 factors compared between the two stocks.

How does Smart for Life compare to Orgenesis?

Orgenesis (NASDAQ:ORGS) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Smart for Life has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orgenesis$662K3.51-$55.36M-$11.51N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

In the previous week, Smart for Life had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Orgenesis. Orgenesis' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Orgenesis Neutral
Smart for Life Neutral

Smart for Life has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
Orgenesis-3,827.81% N/A -130.18%
Smart for Life N/A N/A N/A

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 1.9% of Orgenesis shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Orgenesis has a beta of 3.06, indicating that its stock price is 206% more volatile than the broader market. Comparatively, Smart for Life has a beta of 13.95, indicating that its stock price is 1,295% more volatile than the broader market.

Summary

Smart for Life beats Orgenesis on 9 of the 11 factors compared between the two stocks.

How does Smart for Life compare to Trevena?

Trevena (NASDAQ:TRVN) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Smart for Life N/A N/A N/A

Smart for Life has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.02-$40.29M-$47.04N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

13.6% of Trevena shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 2.7% of Trevena shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Trevena has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Smart for Life has a beta of 13.95, meaning that its stock price is 1,295% more volatile than the broader market.

In the previous week, Smart for Life had 1 more articles in the media than Trevena. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Trevena. Trevena's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Trevena Neutral
Smart for Life Neutral

Summary

Smart for Life beats Trevena on 9 of the 10 factors compared between the two stocks.

How does Smart for Life compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Smart for Life N/A N/A N/A

In the previous week, Smart for Life had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Smart for Life and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Smart for Life Neutral

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Smart for Life has a beta of 13.95, suggesting that its stock price is 1,295% more volatile than the broader market.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Smart for Life. Smart for Life is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Navidea Biopharmaceuticals on 5 of the 8 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMFL vs. The Competition

Export
MetricSmart for LifeMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$7K$3.74B$6.30B$12.11B
Dividend YieldN/AN/A2.80%5.36%
P/E Ratio0.009.2020.8225.31
Price / Sales0.002.05514.3771.03
Price / CashN/A7.5343.1855.00
Price / Book0.001.619.886.94
Net Income-$22.68M$10.91M$3.55B$335.25M
7 Day PerformanceN/A-1.16%-0.83%-1.39%
1 Month PerformanceN/A10.44%-1.19%0.09%
1 Year PerformanceN/A23.38%33.66%32.51%

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/A$0.00
+11.1%		N/A+400.0%$7K$11.11MN/A110
VAXX
Vaxxinity
N/A$0.00
flat		N/A-96.7%$13KN/AN/A90
ELOX
Eloxx Pharmaceuticals
N/A$0.00
flat		N/A+548,900.0%$11KN/AN/A30
ORGS
Orgenesis
N/A$0.00
-95.3%		N/A-77.6%$11K$662KN/A150
TRVN
Trevena
N/A$0.01
flat		N/A-99.0%$11K$443KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 5/21/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel